组蛋白脱乙酰化酶抑制剂在心血管疾病中的研究进展  

Research Progress of Histone Deacetylase Inhibitors in Cardiovascular Diseases

作　　者：周桐如 孔澳霞 吴雅馨 杜钰 汪晨净[1] Zhou Tongru;Kong Aoxia;Wu Yaxin;Du Yu;Wang Chenjing(Health Science Center of Northwestern Minzu University,Lanzhou 730030,Gansu,China)

机构地区：[1]西北民族大学医学部,兰州730030

出　　处：《青海科技》2022年第4期199-202,共4页Qinghai Science and Technology

基　　金：兰州市科技计划医疗卫生专项项目“组蛋白脱乙酰酶6抑制剂ACY1215减轻血管平滑肌细胞炎症反应及动脉粥样硬化斑块易损性的实验研究”(项目编号:2021-1-133);甘肃省自然科学基金计划项目“异鼠李素对TNF-α诱导的血管平滑肌细胞增殖和炎症反应的影响及其信号转导机制研究”(项目编号:20JR5RA503);西北民族大学本科生科研能力训练项目“组蛋白脱乙酰酶6抑制剂ACY-1215对ox-LDL诱导血管平滑肌细胞炎症及增殖反应的影响及其机制研究”(项目编号:XBMU21173)。

摘　　要：组蛋白脱乙酰化酶(histone deacetylase,HDAC)是一类主要通过与底物蛋白相互作用而参与和调控多种生物学进程的蛋白酶。大量研究发现,在神经退行性疾病、肿瘤及心血管疾病等诸多疾病中HDAC与其均有关联。近年来的研究表明HDAC抑制剂(histone deacetylase inhibition,HDACi)不仅对肿瘤性疾病起着很好的抑制作用,在心血管疾病的诊治过程中也发挥着独特的作用,更重要的是对正常细胞几乎没有细胞毒性,因此已逐渐成为科研和临床实践中的“香饽饽”。文章综述了HDACi在心血管疾病中的研究进展,为其以后相关的科研研究提供一些证据,使其能更好地应用于临床心血管疾病。Histone deacetylase(HDAC)is a class of proteases that participate in and regulate multiple biological processes primarily by interacting with substrate proteins.A large number of studies have found that HDAC is associated with many diseases such as neurodegenerative diseases,tumors and cardiovascular diseases.And recent studies have shown that HDAC inhibition(histone deacetylase inhibition,HDACi)not only play a good inhibitory role in tumor diseases,but also play a unique role in the diagnosis and treatment of cardiovascular diseases and occupy a place.More importantly,there is almost no cytotoxicity to normal cells.Therefore,it has gradually become a“fragrant food”in scientific research and clinical practice.This paper reviews the research progress of HDACi in cardiovascular diseases,and provides some evidence for its future related scientific research studies,so that it can be better applied to clinical cardiovascular diseases.

关 键 词：组蛋白脱乙酰化酶抑制剂 心血管疾病 动脉粥样硬化 

分 类 号：R54[医药卫生—心血管疾病]